XML 56 R35.htm IDEA: XBRL DOCUMENT v3.24.2
Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments
Derivative instruments were recorded at fair value in the condensed consolidated balance sheets as follows:
 As of June 30, 2024As of December 31, 2023
Asset
Derivatives
Liability
Derivatives
Asset
Derivatives
Liability
Derivatives
 (in millions)
Derivatives designated as
accounting hedges:
Interest rate contracts$145 $59 $120 $57 
Net investment hedge derivative contracts (1)
229 128 163 382 
$374 $187 $283 $439 
Derivatives not designated as
   accounting hedges:
Currency exchange contracts$213 $85 $195 $134 
Commodity contracts4,912 4,221 1,119 984 
Interest rate contracts— — 
$5,126 $4,306 $1,314 $1,120 
Total fair value$5,500 $4,493 $1,597 $1,559 

(1)Net investment hedge derivative contracts consist of cross-currency interest rate swaps, forward contracts and options. We also designate some of our non-U.S. dollar denominated debt to hedge a portion of our net investments in our non-U.S. operations. This debt is not reflected in the table above, but is included in long-term debt discussed in Note 8, Debt and Borrowing Arrangements. Both net investment hedge derivative contracts and non-U.S. dollar denominated debt acting as net investment hedges are also disclosed in the Derivative Volume table and the Hedges of Net Investments in International Operations section appearing later in this footnote.
Fair Value of Offsetting Assets
We recorded the fair value of our derivative instruments in the condensed consolidated balance sheet as follows:

 As of June 30, 2024As of December 31, 2023
 (in millions)
Other current assets
$5,082 $1,347 
Other assets
418 250 
Other current liabilities
4,139 1,209 
Other liabilities
354 350 
Fair Value of Offsetting Liabilities
We recorded the fair value of our derivative instruments in the condensed consolidated balance sheet as follows:

 As of June 30, 2024As of December 31, 2023
 (in millions)
Other current assets
$5,082 $1,347 
Other assets
418 250 
Other current liabilities
4,139 1,209 
Other liabilities
354 350 
Summary of Derivative Instrument Fair Value Measurement Inputs
The fair values (asset/(liability)) of our derivative instruments were determined using:
 As of June 30, 2024
 Total
Fair Value of Net
Asset/(Liability)
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Currency exchange contracts$128 $— $128 $— 
Commodity contracts691 (58)749 — 
Interest rate contracts87 — 87 — 
Net investment hedge contracts101 — 101 — 
Total derivatives$1,007 $(58)$1,065 $— 
 As of December 31, 2023
 Total
Fair Value of Net
Asset/(Liability)
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Currency exchange contracts$61 $— $61 $— 
Commodity contracts135 28 107 — 
Interest rate contracts61 — 61 — 
Net investment hedge contracts(219)— (219)— 
Total derivatives$38 $28 $10 $— 
Schedule of Notional Values of Derivative Instruments
The notional values of our hedging instruments were:
 Notional Amount
 As of June 30,
2024
As of December 31, 2023
 (in millions)
Currency exchange contracts:
Intercompany loans and forecasted interest payments
$6,736 $2,860 
Forecasted transactions
7,732 5,550 
Commodity contracts
20,536 16,631 
Interest rate contracts4,136 2,384 
Net investment hedges:
Net investment hedge derivative contracts8,033 7,456 
Non-U.S. dollar debt designated as net investment hedges:
Euro notes
3,413 3,516 
Swiss franc notes
362 386 
Canadian dollar notes
439 453 
Schedule of Net Investment Hedges
Net investment hedge derivative contract impacts on other comprehensive earnings and net earnings were:
 For the Three Months Ended
June 30,
For the Six Months Ended
June 30,
 2024202320242023
 (in millions)
After-tax gain/(loss) on NIH contracts (1)
$16 $22 $185 $17 

(1)Amounts recorded for unsettled and settled NIH derivative contracts are recorded in the cumulative translation adjustment within other comprehensive earnings. The cash flows from the settled contracts are reported within other investing activities in the condensed consolidated statement of cash flows.
 For the Three Months Ended
June 30,
For the Six Months Ended
June 30,
 2024202320242023
 (in millions)
Amounts excluded from the assessment of hedge effectiveness (1)
$46 $36 $87 $72 

(1)We elected to record changes in the fair value of amounts excluded from the assessment of effectiveness in net earnings within interest and other expense, net.
After-tax gains/(losses) related to hedges of net investments in international operations were recorded within the cumulative translation adjustment section of other comprehensive income and were:

 For the Three Months Ended
June 30,
For the Six Months Ended
June 30,
 2024202320242023
 (in millions)
Euro notes$18 $(17)$79 $(50)
Swiss franc notes(1)(11)19 (16)
Canadian notes(7)11 (8)
Summary of Economic Hedges
Pre-tax gains/(losses) recorded in net earnings for economic hedges were:

 For the Three Months Ended
June 30,
For the Six Months Ended
June 30,
Location of Gain/(Loss) Recognized in Earnings
 2024202320242023
 (in millions) 
Currency exchange contracts:
Intercompany loans and forecasted interest payments$12 $25 $68 $47 Interest and other expense, net
Forecasted transactions
(2)27 23 29 Cost of sales
Forecasted transactions
(2)(2)13 Interest and other expense, net
Forecasted transactions
(6)(1)(6)Selling, general and administrative expenses
Commodity contracts(255)106 929 104 Cost of sales
Equity method investment contracts (1)
— — Gain on equity method investment transactions
Total$(253)$166 $1,019 $190 

(1) Equity method investment contracts consist of the bifurcated embedded derivative option that was a component of the September 20, 2021 €300 million exchangeable bonds issuance and terminates on September 20, 2024. Refer to Note 6, Investments.
Schedule of Contingent Consideration
The following is a summary of our contingent consideration liability activity:

 For the Three Months Ended
June 30,
For the Six Months Ended
June 30,
 2024202320242023
 (in millions)
Liability at beginning of period$703 $659 $680 $642 
Changes in fair value12 (2)35 15 
Payments(54)(90)(54)(90)
Liability at end of period$661 $567 $661 $567 

Contingent consideration was recorded at fair value in the condensed consolidated balance sheets as follows:

 As of June 30, 2024
 Total Fair Value of
Liability
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Clif Bar (1)
$568 $— $— $568 
Other (2)
93 — — 93 
Total contingent consideration$661 $— $— $661 

 As of December 31, 2023
 Total Fair Value of
Liability
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Clif Bar (1)
$548 $— $— $548 
Other (2)
132 — — 132 
Total contingent consideration$680 $— $— $680 

(1)In connection with the Clif Bar acquisition, we entered into a contingent consideration arrangement that may require us to pay additional consideration to the sellers for achieving certain net revenue, gross profit and EBITDA targets in 2025 and 2026 that exceed our base financial projections for the business implied in the upfront purchase price. The other contingent consideration liabilities are recorded at fair value within long-term liabilities. The estimated fair value of the contingent consideration obligation at the acquisition date was determined using a Monte Carlo simulation and recorded in other liabilities. Significant assumptions used in assessing the fair value of the liability include financial projections for net revenue, gross profit, and EBITDA, as well as discount and volatility rates. Fair value adjustments are primarily recorded in selling, general and administrative expenses in the condensed consolidated statement of earnings.
(2)The other contingent consideration liabilities are recorded at fair value, with $93 million and $132 million classified as other current liabilities at June 30, 2024 and December 31, 2023, respectively. Fair value adjustments are recorded in selling, general and administrative expenses in the condensed consolidated statement of earnings. Payment is expected to be made in the third quarter of 2024, and the majority will be classified within cash flows provided by operating activities in the consolidated statement of cash flows.